

Docket No.: TJU0001-107  
PATENT

Appl. Number: 10/621,684  
Filed: 07/17/03

In the Claims:

1-22. (Canceled)

23. (Currently Amended) A pharmaceutical composition comprising:  
a) a ST receptor binding ligand; ~~and~~,  
b) a non-peptide radiostable active agent; and,  
c) a pharmaceutical carrier or diluent.

24. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide.

25. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

26. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

27. (Previously presented ) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

28. (Previously presented ) The pharmaceutical composition of claim 23 wherein said an active agent is a therapeutic agent.

Docket No.: TJU0001-107  
PATENT

Appl. Number: 10/621,684  
Filed: 07/17/03

**29. (Canceled)**

**30. (Previously presented )** The pharmaceutical composition of claim 23 wherein said an active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

**31. (Previously presented )** The pharmaceutical composition of claim 23 wherein said an active agent is 5-fluorouracil.

**32. (Currently Amended)** The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives, ~~trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, galein, saporin, modesein, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.~~

**33. (Previously presented )** The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

Docket No.: TJU0001-107  
PATENT

Appl. Number: 10/621,684  
Filed: 07/17/03

34. (Previously presented ) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

35. (Canceled)

36. (Previously presented ) The pharmaceutical composition of claim 32 wherein said an active agent is 5-fluorouracil.

37. (Canceled)

38. (Currently Amended) The pharmaceutical composition of claim 33 ~~37~~ wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

39. (Currently Amended) The pharmaceutical composition of claim 33 ~~37~~ wherein said an active agent is 5-fluorouracil.

40. (Previously presented ) The pharmaceutical composition of claim 39 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

41. (Previously presented ) The pharmaceutical composition of claim 23 wherein said pharmaceutical composition is an injectable pharmaceutical composition.

42. (Currently Amended ) A ~~The~~ pharmaceutical composition comprising:

- a) a ST receptor binding ligand;
- b) a radiostable active agent; and
- c) a pharmaceutical carrier or diluent;

~~of claim 23~~ wherein said pharmaceutical composition is a liposome comprising a vesicle matrix wherein the ST receptor binding ligand is in the vesicle matrix and the active agent is inside the liposome.

**Docket No.: TJU0001-107**  
**PATENT**

**Appl. Number: 10/621,684**  
**Filed: 07/17/03**

**43. (Previously presented )** The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

**44. (Previously presented )** The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2 said the active agent is 5-fluorouracil.

**45. (New)** The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

**46. (New)** The pharmaceutical composition of claim 42 wherein the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein,

**Docket No.: TJU0001-107  
PATENT**

**Appl. Number: 10/621,684  
Filed: 07/17/03**

abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

**47. (New)** The pharmaceutical composition of claim 42 wherein the active agent is a non-peptide.